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Abstract
Background: Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an important downregulatory
molecule expressed on both T and B lymphocytes. Numerous population genetics studies have
documented significant associations between autoimmune diseases and single nucleotide
polymorphisms (SNPs) within and around the CTLA-4 region of chromosome 2 in man.
Furthermore, circulating levels of a soluble form of CTLA-4 (sCTLA-4) have been reported in a
variety of autoimmune mediated diseases. Despite these findings, the relationship between levels
of sCTLA-4 protein, mRNA transcript levels, and SNPs within the CTLA-4 region have not been
clearly defined. In order to further clarify this relationship, we have tested four different SNPs
within the CTLA-4 region among subjects whom are negative (n = 53) versus positive (n = 28) for
sCTLA-4.
Results: Our data do not support a clear association between sCTLA-4 levels and any of the four
SNPs tested.
Conclusion: The variation in the SNPs tested does not appear to effect sCTLA-4 protein levels,
despite reports that they affect sCTLA-4 mRNA.
Background
Human chromosome region 2q33 contains three genes
known to be involved in immune regulation [1]. Two of
these genes appear to positively regulate immune
responses. These are the CD28 receptor gene and the
inducible co-stimulator (ICOS) gene. A third gene appears
to be a negative regulator of T cell activation; namely,
CTLA-4 [2,3]. It is thus not surprising that genetic varia-
tion within this region is implicated in engendering sus-
ceptibility to autoimmune disease. The CTLA-4 gene
yields at least two major mRNA transcripts in man [4].
One encodes a transmembrane protein that plays an
important role in downregulating T lymphocyte activa-
tion. The other transcript encodes what appears to be a
soluble form of CTLA-4 that lacks a transmembrane
domain, so the protein product should be found in the
extracellular space including blood plasma [5]. We, [6]
and others [7] have identified immunoreactive material in
human plasma that appears to represent the sCTLA-4 pro-
tein. Extensive population genetics studies have suggested
associations between SNPs in and around the CTLA-4
locus on chromosome 2 in man and the presence of
autoimmune disease [8]. The first of these reports was
made by Yanagawa et al [9] in 1995, who found a signifi-
cant association between variation in the (AT) dinucle-
otide repeat within the 3'-untranslated region of the
CTLA-4 gene and the presence of Grave's disease. Subse-
quent to these findings, many others have reported asso-
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region and rheumatoid arthritis [10,11], celiac disease
[12-14], type I diabetes, [15], myasthenia gravis [16,17]
and autoimmune pancreatitis [18]. At the protein level, a
variety of studies have implicated elevated levels of the
sCTLA-4 protein in the plasma of patients with a variety of
immunologically mediated diseases including autoim-
mune thyroid disease [6,19], systemic lupus erythemato-
sus [20] cutaneous systemic sclerosis [21], allergic asthma
[22,23], psoriasis vulgaris [24], and autoimmune pancre-
atitis [25].
In a landmark study of SNP analysis within a 330 kb
region of chromosome 2q33 containing CD28, CTLA-4
and the ICOS gene regions in type I diabetics, Ueda et al
[15] implicated the CT60 SNP (rs3087243) as playing an
important role in the risk of development of diabetes.
Interestingly, the "G" susceptibility allele appeared to be
related to decreased levels of the sCTLA-4 mRNA relative
to those of the full-length (transmembrane encoding)
transcript. Subsequent to this report, a SNP within the
ICOS gene region (IVS+173, also on chromosome 2q33),
was reported to influence alternate splicing of CTLA-4 iso-
forms [26].
Despite the interesting associations between genetic vari-
ation near these immunoregulatory gene regions, mRNA
transcript levels, and blood levels of sCTLA-4, a clear func-
tional relationship between them and the pathogenesis of
autoimmune disease have not been elucidated. We specu-
lated that if the CT60 SNP or other SNPs within and in
proximity of the CTLA-4 gene region were associated with
changes in sCTLA-4 mRNA levels, the same SNPs might
also be associated with changes in the amount of sCTLA-
4 protein in blood plasma. To this end, we selected both
positive and negative (undetectable) plasma samples for
sCTLA-4 and performed SNP analysis for four commonly
tested SNPs within and around the CTLA-4 region. We
found no statistically significant differences in observed
vs. expected genotypic frequencies for these SNPs when
comparing positive vs. negative blood levels of sCTLA-4.
Thus, our data do not support a relationship between
these commonly tested SNPS and circulating levels of




The sample set consisted of 81 serum samples from
patients with a variety of autoimmune disease (n = 54) or
normal adult volunteers without a history of autoimmune
disease (n = 27). They were segregated without reference
to disease status on the basis of the presence or absence of
elevated levels of sCTLA-4 as described below. Blood sam-
ples were obtained following informed consent, and the
study was done under the oversight of our local Institu-
tional Review Board.
Laboratory Analysis
Sera from human subjects were tested in a sandwich
ELISA for sCTLA-4 as previously described [6]. Samples
were categorized as positive or negative for sCTLA-4 based
upon a cutoff optical density of 2.5 fold increase over the
OD450 nm observed when tested against an irrelevant
capture antibody. In general, this corresponded to sCTLA-
4 levels on the order of > 10 ng/ml as defined by commer-
cially available test kits. Triplicate determinations were
made with both anti-CTLA4 and irrelevant capture anti-
bodies.
SNP genotyping was performed on DNA samples
obtained from white blood cell pellets using the Qiagen
mini kit (Chatsworth, CA) as described in the manufactur-
ers instructions. Polymerase chain reaction was used to
amplify DNA fragments including SNPs. PCR products
were digested with appropriate restriction enzymes and
subjected to standard agarose gel electrophoresis for anal-
ysis.
CT60 (rs3087243) genotyping was performed as
described in Vigano et al. [27]. The + 49 A/G (rs231775)
and -318 (rs5742909) SNPs were determined as described
by Harbo et al. [28]. IVS1+173 (rs10932029) T/C geno-
typing was performed as described by Hunt et al. [14].
Statistical Analysis
The Freeman-Halton Extension of the Fisher Exact Test
(two tailed) was used for comparison of the distribution
of observed genotypes for each polymorphism when com-
pared to expected genotypes based upon previously pub-
lished allele frequencies. The following allele frequencies
were used to calculate expected genotypic frequencies:
CT60 A = 0.477, G = 0.523; +49A/G A = 0.642, G = 0.358;
-318 C = 0.91, T = 0.09; IVS+173 T = 0.86, C = 0.14. Allele
frequencies are from Ueda et al. [15], with the exception
of IVS+173, which is from Haimila et al [29]. Expected fre-
quencies were calculated based on the Hardy-Weinberg
formula.
Results and Discussion
We tested 28 individuals who were positive and 53 who
were negative for sCTLA-4 in blood plasma for the pur-
pose of determining whether there was an association
with common SNPs within the CTLA-4 and ICOS regions
of human chromosome 2q33. No evidence of an associa-
tion between levels of sCTLA-4 and SNP genotypes were
found (Table 1.). Furthermore, there were no statistically
significant differences in absolute allele counts between
positive and negative sera (data not shown). Although the
number of samples is rather small, there were no clear cor-Page 2 of 4
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SNP genotypes.
Our data confirm and extend the findings of Purohit and
co-workers [30], who reported a lack of association
between CT60 genotype and sCTLA-4 levels. On the other
hand, our findings appear to be at odds with the specula-
tion that the CTLA-4 CT60-A/G SNP may determine the
alternate splicing and production of the sCTLA-4 mRNA
[15]. In the Ueda model, the CT60-G susceptibility allele
appears to produce lower relative amounts of the sCTLA-
4 mRNA; thus, one would expect that subjects at risk for
autoimmune disease to have reduced levels of sCTLA-4
protein. It seems paradoxical given that lower levels of
CTLA-4 message are present in susceptible individuals
whereas higher levels of sCTLA-4 protein are observed in
plasma of individuals with autoimmune disease. Possible
explanations for the appearance of this discrepancy may
include the possibility that there is no direct relationship
between message levels at the cellular level and circulating
protein in plasma. For example, elevated circulating
sCTLA-4 levels may simply be due to increased half-life
and/or decreased turnover of protein despite increased
levels of synthesis. Also, it is possible that lower levels of
sCTLA-4 message reflect a feedback regulatory loop in
which mRNA levels are reduced in the face of higher levels
of sCTLA-4 protein. Finally, it is possible that immunore-
active CTLA-4 material detected in human serum is not
the direct gene product of the sCTLA-4 mRNA transcript.
While our lab [5,6] has previously reported the presence
of a novel epitope (which is predicted to arise from a
frameshift due to alternate splicing) in immunoprecipi-
tates from CTLA-4 monoclonal antibodies, only a minor-
ity of the material from these immunoprecipitation
experiments is of the predicted molecular mass of the
sCTLA-4 monomer (23 kDa). Thus, it is possible that
ELISA based assays for circulating CTLA-4 levels cannot
distinguish sCTLA-4 monomer produced directly by the
sCTLA-4 transcript within a heterogeneous population of
CTLA-4 immunoreactive material derived from other
sources, such as that derived from proteolytic cleavage
from cells that express the transmembrane protein. There
are numerous examples of soluble receptors that are
derived from such a mechanism including many of the
members of the tumor necrosis factor receptor family as
well as other cytokine receptors and adhesion molecules
[reviewed in [31]]. Despite the finding that the IVS+173
SNP appears to affect the relative level of sCTLA-4 mRNA
[26], our data suggest that the same SNP does not directly
control circulating levels of sCTLA-4 protein. In any case,
the precise mechanism that controls levels of the sCTLA-4
transcript and sCTLA-4 immunoreactive material needs to
be further investigated, but there does not appear to be a
simple relationship between the SNPs that are the object
of study in this report and the sCTLA-4 protein.
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Table 1: Distribution of genotypes of chromosome 2 SNPs among sCTLA-4 positive and negative patients.
sCTLA-4 Pos (N = 28) sCTLA-4 Neg (N = 53)
Polymorphisms Genotypes Observed Expected Observed Expected
AA 8 6 12 12
CT60 AG 12 14 28 26
GG 8 8 13 15
AA 11 11 26 22
+49 A/G AG 14 13 21 24
GG 3 4 6 7
CC 23 23 50 44
-318 C > T CT 4 5 2 8
TT 1 < 1 1 < 1
TT 20 20 38 38
IVS1 +173 T/C TC 8 8 20 15
CC < 1 < 1 < 1 < 1
There were no statistical differences between observed and expected genotype frequencies among either patients positive (Pos) or negative (Neg) 
for sCTLA-4 as determined by ELISA. Data are genotype counts. Expected counts were calculated using the Hardy-Weinberg formula based on 
previously published gene frequencies (15,29). N = number of subjects in each group. See text for definitions of polymorphisms.Page 3 of 4
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